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Abstract
Background: The outcome of patients with bronchiectasis during and after their stay in the
intensive care unit (ICU) has seldom been reported in the literature. Managing these patients in the
ICU can be challenging because of the complex nature of their disease. This study aims to identify
the in-hospital and long-term outcome of patients with bronchiectasis and respiratory failure (RF)
in ICU.
Methods: A retrospective study was carried out by studying all bronchiectatic patients admitted
to the medical ICU for RF over a 10-year period (1995–2004).
Results: The mean (± standard deviation) age of 35 patients was 63.5 ± 11.7 years and APACHE
score was 22.3 ± 7.3. The 4-year mortality was 60%. Among the variables observed, age > 65 years
(hazard ratio (HR): 4.15; 95% confidence interval (CI): 3.2–5.1), APACHE II score > 24 (2.6, 95%
CI 1.7–3.5), intubation (2.81, 95 %CI 1.9–3.7), inotropic support (2.9, 95% CI 2.0–3.7), Home-O2
(4.0, 95% CI 2.7–5.2) and activity index (4.0, 95% CI 2.8–5.3) were associated with diminished
survival in univariate analysis by Cox regression. By long rank test, survival probabilities were
significantly low at these strata. Multivariate analysis of Cox proportional hazard model showed
that age > 65 years (HR: 5.4, 95% CI 1.9–15.7); activity index (HR: 4.8, 95% CI 1.4–16.6); and
inotropic support (HR: 3.8, 95% CI 1.5–10.1) were independently associated with reduced survival.
Conclusion: The decreased survival of ICU patients was associated with age > 65 years, activity
index (bedridden or wheelchair-bound) and use of inotropic support.
Background
Bronchiectasis is an abnormal dilatation of the bronchial
wall that is generally caused by infection [1]. Recurrent
respiratory symptoms are common; however, the inci-
dence of advanced bronchiectasis is now declining. Most
patients are treated with a combination of postural drain-
age, antibiotics, and inhalation therapy [2,3]. Some
patients need resectional surgery, which may cure the dis-
ease [4]. However, some patients may require intensive
care therapy for acute respiratory failure (RF). Such
patients may present with advanced RF and require
assisted ventilation. Managing these patients in the inten-
sive care unit (ICU) can be challenging because of the
complex nature of their disease. Excessive sputum produc-
tion, significant airway inflammation [5,6], and a change
of chest wall geometry make their weaning from mechan-
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ical ventilation a burdensome process that is usually com-
plicated with severe sepsis and multi-organ dysfunction
syndrome (MODS). The ICU and long-term outcomes of
these patients have not been fully analyzed. Moreover, the
role of quality of life thereafter in the outcome for those
who were successfully discharged has not been defined.
We therefore decided to study the outcome of patients
with bronchiectasis and chronic RF who require ICU
admission, as well as factors that influence mortality, par-
ticularly the functional status of these patients.
Methods
Patients
This study was conducted in the medical ICU of King Kha-
lid University Hospital, Riyadh, Saudi Arabia. The charts
of all patients who were admitted with the diagnosis of
bronchiectasis between January 1996 and January 2004
were reviewed. The study was approved by the Deanship
of Scientific Research of King Saud University and the
Research Ethics Committee of King Khalid University
Hospital, Riyadh, Saudi Arabia. All patients were diag-
nosed by high-resolution CT scan (HRCT) based on previ-
ously reported criteria and had no limitations or
withdrawal from therapy [7]. Patients were excluded if
they had cystic fibrosis, were younger than 14, or were
admitted for reasons other than RF.
Demographic data were age, gender, history of smoking,
childhood infections, history of mycobacterium tubercu-
losis (TB) exposure, and long-term therapy of home oxy-
gen (Home-O2). Symptoms of acute exacerbation such as
shortness of breath, cough, sputum production, haemop-
tysis, and wheezes were included. Interventions that
included mechanical ventilation (MV), inotropic support,
and duration of ICU stay were recorded. Patients who
underwent non-invasive mechanical ventilation (NIMV)
were generally conscious with disturbed respiratory phys-
iology. Puritan Bennett 7200 or Bennett 840 was used by
applying two pressure levels [pressure support and posi-
tive end expiratory pressure (PEEP)]. Acidemic patients
(pH < 7.25 and PCO2 > 55 mmHg) and those with unsta-
ble haemodynamics were intubated and ventilated with a
volume targeted mode. Previous spirometry was meas-
ured with standard protocol recommended by the Euro-
pean Respiratory Society [8]. Obstructive ventilatory
impairment is characterized by a low forced expiratory
volume/s (FEV1) with relatively normal forced vital capac-
ity (FVC), reduction of FEV1, FVC. FEV1/FVC % indicates
mixed obstructive-restrictive ventilatory impairment.
Assessment of severity
The worst physiological variable in the first 24 hours was
used to calculate the Acute Physiology and Chronic
Health Evaluation (APACHE II) score [9]. Premorbid dys-
pnea was scored according to the American Thoracic Soci-
ety (ATS) scale [10]. The activities of daily living were
recorded as 0 = working; 1 = independent (fully ambula-
tory and living without any assistance); 2 = restricted (able
to live on their own and leave their homes to perform
basic tasks, but severally limited in exercise ability); 3 =
housebound (cannot leave their homes unassisted or
leave their homes rarely, able to perform self-care but una-
ble to do heavy chores such as house cleaning, cannot live
alone, and may be institutionalized; and 4 = bedridden or
wheelchair-bound.
Outcome and long-term follow-up
The outcome is defined as survival and discharge from
hospital. The charts of those who were successfully dis-
charged were reviewed over a period of 4 years. When the
follow-up was lost, the principal investigator contacted
the patient's relatives. If the patient was deceased, the
exact date of death was recorded.
Statistical analysis
Descriptive statistics (mean and standard deviation) were
calculated for all continuous variables. Survival was calcu-
lated from the data of patients who either survived up to
4 years or died within 4 years of being discharged from the
hospital. Log-rank test was used to compare the survival
pattern between the two strata of study variables. Univar-
iate Cox regression was used to identify factors that were
significantly associated with lower survival. The Cox pro-
portional hazards model was used to identify the inde-
pendent predictors associated with reduced survival.
Patients who survived to the end of the follow-up period
were considered censored. The analysis was done with
SPSS pc+ version 10.0 software; p < 0.05 was considered
to be statistically significant.
Results
The 35 adults with bronchiectasis were studied retrospec-
tively over 4 years. Mean age was 63.5 ± 11.7; 21 (60%)
were females. All patients were in respiratory failure need-
ing assisted ventilation. Cough was prevalent in 29
(82.8%) patients, sputum production was reported in 26
(74.3%), and 10 (29.9%) had haemoptysis. The etiology
of bronchiectasis was found in 17 (48.6%) patients based
on x-ray findings of old TB and 6 of them had received
antituberculous chemotherapy. Twenty-five patients
(71.4%) were treated with long-term Home-O2 therapy.
Activity of daily living was identified as bedridden or
wheelchair-bound in 24 (68.6%) cases and 8 (22.8%)
patients were independent or restricted. CT scans demon-
strated that four lobes or more were involved in 12 cases
(34.3%) and that at least three lobes were involved for 5
(14.3%) patients.
Spirometry results were available for 23 (65.7%) patients.
The mean FEV1 was 2.01 ± 0.46 L/s. The physiological sta-BMC Pulmonary Medicine 2007, 7:17 http://www.biomedcentral.com/1471-2466/7/17
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tus of the patients at ICU admission is reported in Table 1.
Eleven patients (31.4%) were intubated before being
admitted to the ICU or within the first day after their
admission. In 4 patients (11.4%), PaO2 while breathing
room air was < 60 mmHg. PaCO2 for 23 patients (65.7%)
was > 55 mmHg or pH < 7.30 while on oxygen therapy.
Diabetes mellitus was noted in 8 patients (22.8%); hyper-
tension was present in 9 patients (25.7%), 7 patients
(20%) had renal disease; liver disease was present in 9
patients (25.7%) and 6 (17%) were smokers.
Risk factors for mortality in the ICU and after ICU stay
NIMV was used for 20 patients (57.1%). Eleven patients
(31.4%) required intubation. Twelve (34.3%) died during
ICU stay; all these had required intubation. ICU stays
were 6.7 ± 7.3 days for survivors (range 1–28 days) and
14.5 ± 15.3 days for non-survivors (range 1–50 days). The
mean FEV1 for survivors was 2.9 ± 0.6 and 0.9 ± 0.3 L/s for
non-survivors. The median follow-up was 240 days (range
1–1,460 days). Cumulative mortality was 34.3% (n = 12)
in ICU and 60% (n = 21) at 4 years. The causes of in-hos-
pital deaths were: in 6 patients, complications of RF and
MODS; in 2, myocardial infarction; in 1, presumed pul-
monary embolism; and in 3, undetermined. The risk fac-
tors for hospital mortality by univariate analysis are
shown in Table 2. Gender did not differentiate patient
outcomes after ICU discharge. Survival decreased for
patients who were older than 65, had an APACHE score >
24, were intubated, and who needed inotropic support,
Home-O2, and were bedridden or chair-bound. Compari-
sons by the log-rank tests were significant (age > 65, p <
0.01; inotropic support, p = 0.01; and activity index, p =
0.01).
The results of the Cox proportional hazards analysis of
factors associated with increased mortality after the ICU
admission for RF are shown in Table 3. We included the
dichotomous variables in multivariate analysis as patients
attained a p-value of 0.5: age (> 65 vs. ≤ 65); APACHE
score (> 24 vs. ≤ 24); intubation required (yes/no); ino-
tropic support (yes/no); use of Home-O2 (yes/no); activi-
ties of living (bedridden or wheelchair-bound vs.
working, independent, and restricted). Age > 65 (HR, 5.4;
95% CI, 1.9 to 15.7), inotropic support (HR, 3.8; 95% CI,
1.5, 10.1), and activity index (HR, 4.8; 95% CI, 1.4, 16.6)
were independently associated with reduced survival. The
Cox model survival curve for two categories of activity
index is provided in Fig. 1, which indicates poor survival
for patients who were bed/chair bound when compared
with patients who were independent and restricted.
Discussion
The studies of long- and short-term outcome of bron-
chiectasis are scarce in the medical literature [11-13]; the
clinical studies of patients managed in ICU are even fewer.
A literature search found only one other study that evalu-
ated ICU survival of patients with bronchiectasis [11].
This is likely because researchers concentrated on chronic
obstructive pulmonary disease (COPD), which is more
common than bronchiectasis in western countries. Bron-
chiectasis has recently declined, but still occurs in devel-
oping countries [14,15]. The in-hospital mortality in this
group was 34.3%; and 4-year cumulative mortality was
60%. The major factors that influenced in-hospital mor-
Survival curve for two categories of activity index using Cox  model Figure 1
Survival curve for two categories of activity index using Cox 
model.
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Table 2: Risk Factors for hospital mortality (by univariate 
analysis).
Variables HR (95% C.I) p-value
Male gender 1.9 (0.7, 4.9) 0.12
Age > 65 years 4.1 (3.2, 5.1) < 0.01
APACHE II Score > 24 2.6 (1.7, 3.5) 0.03
Intubation 2.8 (1.9, 3.7) 0.02
Inotropic support 2.8 (2.0, 3.7) 0.02
Home-O2 4.0 (2.7, 5.2) 0.02
Activity Index 4.0 (2.8, 5.3) 0.03
Table 1: Variables of 35 patients with bronchiectasis at ICU 
admission.
Variables Mean ± S.D.
Age (years) 63.5 ± 11.7
APACHE II score 22.3 ± 7.3
pH 7.3 ± 0.1
PaO2 (mmHg) 66.9 ± 34.1
PaCO2 (mmHg) 73.5 ± 25.1
FEV (L/s) 2.0 ± 4.6BMC Pulmonary Medicine 2007, 7:17 http://www.biomedcentral.com/1471-2466/7/17
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tality and subsequent death were age > 65, inotropic sup-
port, and premorbid level of activities.
In a recent retrospective study, DuPont et al. reported the
mortality of their patients with bronchiectasis. Nineteen
percent died in ICU and the 1-year mortality rate was
40%. Our findings on mortality are worse than they
reported because the populations studied were mostly in
advanced stages of the disease. Seventy-eight percent of
our patients were using home O2 and 57% required NIMV
compared to 25% and 27%, respectively, in the DuPont
study [11]. Moreover, cylindrical bronchiectasis was seen
in 56% of their patients whereas in our study, we found
that 78% of our patients had cystic bronchiectasis, which
suggests that our patients had more severe disease. Ashour
suggested that cystic changes can worsen in pulmonary
haemodynamics and more deterioration in gas exchange
compared to cylindrical changes [16].
Univariate and multivariate analysis showed that premor-
bid level of activity was the independent determinant of
outcome among our patients. This association has not
been examined previously in bronchiectatic patients. Pre-
vious studies have shown functional status to be an
important predictor of outcome for patients with COPD
and RF, especially at 1 year or long term follow-up
[17,18]. Based on these findings, patients with bron-
chiectasis who develop acute RF, require ICU admissions,
and have poor functional status tend to have chronic pro-
gressive disease after their discharge. Their long-term
prognosis is dismal.
Our results are also in accordance with the findings of
Symonds  et al., who conducted a prospective study of
domiciliary nasal intermittent positive pressure ventila-
tion in hypercapnic RF and found that only 20% of
patients with bronchiectasis survived after 2 years com-
pared to more favorable results in patients with scoliosis,
previous poliomyelitis, or COPD [19].
In another study, Keistinen et al. reviewed the National
Hospital Discharge Register in Finland and reported that
patients with bronchiectasis had a more favorable out-
come than those with COPD, but a less favorable out-
come than asthmatics [12]. Variations between these
studies may be ascribed to differences in severity of dis-
ease and disparity in population studied. The finding of
low quality of life in this study highlighted important
opportunities for improved care. For example, pulmonary
rehabilitation, particularly postural drainage and behav-
ioral therapy, appear to improve the quality of life in
patients with COPD [20,21]. It has been shown also
recently that, pulmonary rehabilitation is effective in
improving exercise tolerance in bronchiectatic patients
[22]. Selective patients may inhale antibiotics to reduce
bacterial colonization, which will eventually reduce the
probability of infection [23]. Moreover, immunization or
vaccination in this high-risk group is important to prevent
or minimize exacerbation.
Age was a statistically significant determination of 1-year
and 4-year survival in this study. The association of age
with long-term mortality risk could be modulated by
other diseases and the severity of the acute illness. The
abnormal physiology and the complications that develop
during ICU stay strongly influence the patient's outcome.
APACHE II score has been tried as a model of predictive
survival in general ICU, but has not previously been eval-
uated in bronchiectatic patients. In this study, APACHE II
score > 24 (p = 0.03) was associated with diminished sur-
vival in univariate analysis by lot regression. Moreover,
the mean FEV1 for survivors was 2.9 ± 6 compared to 0.9
± 0.3 for non-survivors.
Mechanical ventilation was associated with in-hospital
mortality for our patients (Table 2). However, it was not
an independent predictor of long-term mortality with
multivariate analysis. The increased mortality of intu-
bated patients was likely due to high APACHE II score.
The in-hospital and long-term survival were also poor for
patients who required inotropic support. This suggests
that their haemodynamic instability was likely due to sep-
sis or other reasons such as cor pulmonale, which could
eventually affect the left ventricular function [24]. System-
atic cardiac function was not evaluated in this cohort.
The study has several inherent limitations. Because of the
retrospective review of a prescreened population, the
results may be biased by selection. Some results were
missing or incomplete, which could have an impact on
our statistics. Moreover, systematic nutritional assess-
ment, which could affect mortality, was not performed.
Finally, the population studied was relatively small to
enable us to draw a short conclusion.
Conclusion
We found that in-hospital and long-term outcome of
patients with bronchiectasis can be predicted by taking in
to account, age, interventions in the ICU, and severity
Table 3: Results of Cox Proportional Hazard Model analysis of 
the risk of death after the ICU admission for Respiratory Failure 
among 35 patients with Bronchiectasis.
Predictor variables HR 95% C.I. p-value
Age > 65 years 5.4 (1.9, 15.7) 0.002
Inotropic support 3.8 (1.5, 10.1) 0.006
Activity Index 4.8 (1.4, 16.6) 0.013BMC Pulmonary Medicine 2007, 7:17 http://www.biomedcentral.com/1471-2466/7/17
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score. We observed poor functional status, which may
reflect the poor physical reserve in these patients.
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